Aliases & Classifications for Peritoneum Cancer

MalaCards integrated aliases for Peritoneum Cancer:

Name: Peritoneum Cancer 12 15
Peritoneal Neoplasm 12 17
Malignant Tumor of Peritoneum 71
Cancer of Peritoneum 12
Peritoneal Neoplasms 71


External Ids:

Disease Ontology 12 DOID:1725
ICD9CM 34 158.8
ICD10 32 C48.1 C48.2
UMLS 71 C0031149 C0153466 C0153467

Summaries for Peritoneum Cancer

Disease Ontology : 12 An organ system cancer that is located in the peritoneum.

MalaCards based summary : Peritoneum Cancer, also known as peritoneal neoplasm, is related to peritoneal mesothelioma and carcinosarcoma, and has symptoms including sister mary joseph's nodule An important gene associated with Peritoneum Cancer is CALB2 (Calbindin 2), and among its related pathways/superpathways are Pathways in cancer and Homologous DNA Pairing and Strand Exchange. The drugs Ifosfamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include breast, colon and ovary, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with cisplatin

Related Diseases for Peritoneum Cancer

Diseases related to Peritoneum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 371)
# Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 31.6 WT1 NF2 CEACAM5 CDKN2A CALB2 BAP1
2 carcinosarcoma 29.8 WT1 TP53 PAX8 KRT7 CALB2
3 papillary adenocarcinoma 29.7 TP53 KRT7 CEACAM5 BRCA2 BRCA1
4 benign mesothelioma 29.2 WT1 PTGER4 PAX8 KRT7 KRT5 CEACAM5
5 hereditary site-specific ovarian cancer syndrome 10.6 BRCA2 BRCA1
6 clear cell cystadenofibroma 10.6 TP53 CALB2
7 rare malignant breast tumor 10.6 BRCA2 BRCA1
8 lung leiomyosarcoma 10.6 KRT5 CALB2
9 synchronous bilateral breast carcinoma 10.6 BRCA2 BRCA1
10 rete testis adenoma 10.6 PAX8 CALB2
11 breast juvenile papillomatosis 10.6 BRCA2 BRCA1
12 spermatic cord cancer 10.6 WT1 KRT5
13 pax6-related aniridia 10.6 WT1 BRCA2
14 familial ovarian cancer 10.6 BRCA2 BRCA1
15 tetraploidy 10.6 BRCA2 BRCA1
16 cancerophobia 10.6 BRCA2 BRCA1
17 thymus basaloid carcinoma 10.6 PAX8 KRT5
18 fallopian tube adenocarcinoma 10.6 CALB2 BRCA1
19 fallopian tube squamous cell carcinoma 10.6 WT1 CDKN2A
20 nevus of ota 10.6 TP53 BAP1
21 nephrogenic adenofibroma 10.6 WT1 KRT7
22 nosophobia 10.5 BRCA2 BRCA1
23 ceruminoma 10.5 KRT7 KRT5
24 benign breast adenomyoepithelioma 10.5 KRT7 KRT5
25 breast adenomyoepithelioma 10.5 KRT7 KRT5
26 subareolar duct papillomatosis 10.5 KRT7 KRT5
27 peritoneal serous papillary adenocarcinoma 10.5 WT1 PTGER4
28 bone leiomyosarcoma 10.5 KRT7 KRT5
29 nipple neoplasm 10.5 KRT7 KRT5
30 sarcomatoid basal cell carcinoma 10.5 PTGER4 KRT5
31 nephrogenic adenoma of urinary bladder 10.5 PAX8 KRT7
32 pericardial mesothelioma 10.5 MIR1266 KRT5 CALB2
33 wolffian duct adenoma 10.5 PAX8 KRT7
34 esophageal basaloid squamous cell carcinoma 10.5 TP53 KRT5
35 testicular fibroma 10.5 WT1 KRT5 CALB2
36 fallopian tube carcinosarcoma 10.5 WT1 TP53 CALB2
37 liver fibroma 10.5 MSLN KRT5 CALB2
38 cervical basaloid squamous cell carcinoma 10.5 KRT7 CDKN2A
39 ceruminous adenocarcinoma 10.5 KRT7 KRT5
40 asbestosis 10.5 WT1 MSLN CALB2
41 epididymal neoplasm 10.5 WT1 KRT7 CALB2
42 bartholin's gland adenocarcinoma 10.5 PTGER4 KRT7
43 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A
44 breast cystic hypersecretory carcinoma 10.5 KRT5 CEACAM5
45 cervical serous adenocarcinoma 10.5 WT1 CEACAM5
46 endometrial transitional cell carcinoma 10.5 KRT7 CDKN2A
47 malignant acrospiroma 10.5 KRT5 CEACAM5
48 gallbladder squamous cell carcinoma 10.5 KRT5 CEACAM5
49 ovarian sex-cord stromal tumor 10.5 WT1 KRT7 CALB2
50 gastric squamous cell carcinoma 10.5 KRT7 KRT5

Comorbidity relations with Peritoneum Cancer via Phenotypic Disease Network (PDN):

Ovarian Cancer

Graphical network of the top 20 diseases related to Peritoneum Cancer:

Diseases related to Peritoneum Cancer

Symptoms & Phenotypes for Peritoneum Cancer

UMLS symptoms related to Peritoneum Cancer:

sister mary joseph's nodule

GenomeRNAi Phenotypes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BAP1 BRCA1 BRCA2 RAD51C RAD51D TP53
2 Synthetic lethal with cisplatin GR00101-A-1 8.8 BRCA1 BRCA2 NF2

MGI Mouse Phenotypes related to Peritoneum Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 BAP1 BRCA1 BRCA2 CDKN2A EPCAM KRT7
2 cardiovascular system MP:0005385 10.18 BAP1 BRCA1 CDKN2A EPCAM PAX8 PTGER4
3 growth/size/body region MP:0005378 10.18 BAP1 BRCA1 BRCA2 CDKN2A EPCAM KRT5
4 embryo MP:0005380 10.17 BAP1 BRCA1 BRCA2 CDKN2A EPCAM NF2
5 homeostasis/metabolism MP:0005376 10.17 BAP1 BRCA1 BRCA2 CDKN2A EPCAM KRT7
6 endocrine/exocrine gland MP:0005379 10.1 BAP1 BRCA1 BRCA2 CDKN2A EPCAM NF2
7 mortality/aging MP:0010768 9.97 BAP1 BRCA1 BRCA2 CDKN2A EPCAM KRT5
8 limbs/digits/tail MP:0005371 9.8 BRCA1 BRCA2 KRT5 PAX8 RAD51D SLC13A5
9 neoplasm MP:0002006 9.56 BAP1 BRCA1 BRCA2 CDKN2A NF2 PTGER4
10 no phenotypic analysis MP:0003012 9.23 BAP1 CDKN2A EPCAM KRT5 PAX8 SLC13A5

Drugs & Therapeutics for Peritoneum Cancer

Drugs for Peritoneum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ifosfamide Approved Phase 3 3778-73-2 3690
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
lanreotide Approved Phase 3 108736-35-2
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
Nintedanib Approved Phase 3 656247-17-5 56843413
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
Pembrolizumab Approved Phase 3 1374853-91-4
Olaparib Approved Phase 3 763113-22-0 23725625
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
Fluorouracil Approved Phase 3 51-21-8 3385
leucovorin Approved Phase 3 58-05-9 6006 143
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
Epirubicin Approved Phase 3 56420-45-2 41867
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
Raltitrexed Approved, Investigational Phase 3 112887-68-0 104758
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
Trebananib Investigational Phase 3 894356-79-7
25 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
Isophosphamide mustard Phase 3 0
27 Protective Agents Phase 3
28 Epothilone B Phase 3
29 Epothilones Phase 3
30 Angiopeptin Phase 3
31 Antidotes Phase 3
32 Calcium, Dietary Phase 3
33 Trace Elements Phase 3
34 Micronutrients Phase 3
35 Carotenoids Phase 3
36 Antineoplastic Agents, Immunological Phase 3
37 Antibodies, Monoclonal Phase 3
38 Immunoglobulins Phase 3
39 Antibodies Phase 3
40 Angiogenesis Inhibitors Phase 3
41 Antimitotic Agents Phase 3
42 Albumin-Bound Paclitaxel Phase 3
43 Mitomycins Phase 3
44 taxane Phase 3
45 Mitogens Phase 3
46 Endothelial Growth Factors Phase 3
47 Immunoglobulin G Phase 3
48 Anesthetics Phase 3
49 Dialysis Solutions Phase 3
s 1 (combination) Phase 3

Interventional clinical trials:

(show top 50) (show all 286)
# Name Status NCT ID Phase Drugs
1 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
2 Concentration-based Versus Body Surface Area-based Peroperative Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis' Treatment - Randomized Non-blinded Phase III Clinical Trial Unknown status NCT03028155 Phase 3 Oxaliplatin: BSA-based HIPEC;Oxaliplatin: Concentration-based HIPEC
3 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
4 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
5 A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
6 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
7 Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Completed NCT01015118 Phase 3 Placebo;Paclitaxel;BIBF 1120;Carboplatin;Paclitaxel;Carboplatin
8 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
9 A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. Completed NCT01524094 Phase 3 Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
10 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
11 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
12 Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
13 Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer Completed NCT00769405 Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
14 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
15 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
16 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
17 A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma Completed NCT00052962 Phase 3
18 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
19 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
20 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
21 Randomized Multicentric Phase III Trial Comparing Simple Surgery to Surgery Plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy) With MMC in Colorectal Patients Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis Recruiting NCT02179489 Phase 3
22 Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Recruiting NCT03348150 Phase 3 Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
23 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001/ENGOT-ov43) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
24 Multi-center, Randomized Controlled, Phase III Trials to Evaluate the Safety and Effectiveness After Cycles Reduction of Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Recruiting NCT03693248 Phase 3 Two cycles of neoadjuvant chemotherapy
25 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
26 Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis Recruiting NCT02840331 Phase 3 St. John's Wort
27 Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study Recruiting NCT02758951 Phase 2, Phase 3
28 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
29 A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
30 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
31 Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction Active, not recruiting NCT02158988 Phase 3
32 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
33 Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis Active, not recruiting NCT02231086 Phase 3 Standard adjuvant systemic chemotherapy
34 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
35 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
36 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Systemic Chemotherapy And Cytoreductive Surgery (CRS) in the Treatment of Peritoneal Carcinomatosis From Gastric Cancer Not yet recruiting NCT03179579 Phase 3
37 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) Not yet recruiting NCT04111978 Phase 3 Letrozole 2.5mg
38 Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer Terminated NCT01683864 Phase 2, Phase 3 positive cytology with HIPEC
39 Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Unknown status NCT02435186 Phase 2 p53 gene;Cisplatin;Paclitaxel
40 Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer Unknown status NCT01575730 Phase 2 Hyperthermic intraoperative Peritoneal Chemoperfusion
41 A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Unknown status NCT01570582 Phase 2 carboplatin and paclitaxel
42 Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin Unknown status NCT00766142 Phase 2 fluorouracil;leucovorin calcium;oxaliplatin
43 Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial Unknown status NCT00454519 Phase 2
44 Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum Unknown status NCT01100372 Phase 2 gemcitabine hydrochloride;liposome-encapsulated doxorubicin citrate
45 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
46 A Phase II Trial of Avastin in Combination With Docetaxel in Patients With Recurrence of Epithelial Carcinoma of the Ovary/Fallopian Tube/Peritoneum Within 12 Months of Platinum Therapy Completed NCT00504257 Phase 2 Avastin;Docetaxel
47 A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire Completed NCT00517621 Phase 2 Paclitaxel;EPO
48 A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer Completed NCT00074867 Phase 2 CP-547,632
49 An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Completed NCT00035100 Phase 2 epothilone b
50 Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia Completed NCT02739698 Phase 2 Paclitaxel

Search NIH Clinical Center for Peritoneum Cancer

Genetic Tests for Peritoneum Cancer

Anatomical Context for Peritoneum Cancer

MalaCards organs/tissues related to Peritoneum Cancer:

Breast, Colon, Ovary, T Cells, Liver, Thymus, Lung

Publications for Peritoneum Cancer

Articles related to Peritoneum Cancer:

(show all 27)
# Title Authors PMID Year
[Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. 61
30686730 2019
Metachronous occurrence of two different histological subtypes of endometriosis-related neoplasms. 61
30603661 2019
Changes in the Management and Prognosis of Ovarian Cancer Due to the New FIGO and WHO Classifications: A Case Series Observational Descriptive Study. Seven Years of Follow-up. 61
30045138 2018
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. 61
29206890 2018
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. 61
26907364 2016
Progression of peritoneal adenomucinosis to the scrotum: a rare occurrence treated with cytoreductive surgery and hyperthermic chemoperfusion of the scrotum in two patients. 61
25100893 2014
Epidemiology of cancers in Serbia and possible connection with cyanobacterial blooms. 61
25436472 2014
From bacteria to antineoplastic: epothilones a successful history. 61
23343081 2013
Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. 61
21874229 2011
Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. 61
21543188 2011
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. 61
20414103 2010
Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. 61
19361840 2009
The diagnostic problems in patient with ascites, elevated Ca 125 level and autoantibodies against nuclear antigens and smooth muscle antigens mimicking advanced ovarian carcinoma--case study. 61
18624115 2008
Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. 61
17704197 2008
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]. 61
19374245 2008
[Clinical and morphological characteristics of gastrointestinal stromal tumors]. 61
18074824 2007
Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry. 61
17425204 2007
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. 61
16260202 2005
Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. 61
15894368 2005
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. 61
12664303 2003
[Mortality in a cohort of asbestos cement workers in Bari]. 61
12125387 2002
[Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study]. 61
11535965 2001
The hazards of chrysotile asbestos: a critical review. 61
10441898 1999
Cancer mortality among pulp and paper workers in Poland. A cohort study. 61
9187043 1997
[Recurrent ascites in peritoneal mesothelioma. Its diagnostic and therapeutic management]. 61
7742058 1995
The laparoscopic features of certain peritoneal neoplasm. 61
14492250 1962
[Considerations on a case of primary peritoneal neoplasm subjected to local treatment with radiophosphorus]. 61
13805415 1959

Variations for Peritoneum Cancer

Expression for Peritoneum Cancer

Search GEO for disease gene expression data for Peritoneum Cancer.

Pathways for Peritoneum Cancer

GO Terms for Peritoneum Cancer

Cellular components related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 8.96 RAD51D RAD51C
2 replication fork GO:0005657 8.8 TP53 RAD51D RAD51C

Biological processes related to Peritoneum Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.93 TP53 RAD51D RAD51C BRCA2 BRCA1
2 negative regulation of cell proliferation GO:0008285 9.89 WT1 TP53 NF2 CDKN2A BAP1
3 positive regulation of transcription, DNA-templated GO:0045893 9.88 WT1 TP53 PAX8 CDKN2A BRCA2 BRCA1
4 double-strand break repair GO:0006302 9.69 TP53 BRCA2 BRCA1
5 regulation of cell cycle GO:0051726 9.67 TP53 RAD51D NF2 BAP1
6 replicative senescence GO:0090399 9.55 TP53 CDKN2A
7 telomere maintenance via recombination GO:0000722 9.52 RAD51C BRCA2
8 cellular response to gonadotropin stimulus GO:0071371 9.48 WT1 PAX8
9 metanephric S-shaped body morphogenesis GO:0072284 9.46 WT1 PAX8
10 DNA recombination GO:0006310 9.46 RAD51D RAD51C BRCA2 BRCA1
11 metanephric epithelium development GO:0072207 9.43 WT1 PAX8
12 chromosome organization GO:0051276 9.43 TP53 RAD51D BRCA2
13 chordate embryonic development GO:0043009 9.32 BRCA2 BRCA1
14 double-strand break repair via homologous recombination GO:0000724 9.26 RAD51D RAD51C BRCA2 BRCA1
15 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to Peritoneum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 8.92 WT1 TP53 PAX8 BRCA1

Sources for Peritoneum Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....